$FBIO
Fortress Biotech, Inc.

2021 Q2 Form 10-Q Financial Statement

#000155837021011812 Filed on August 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $17.84M $9.457M
YoY Change 88.68% 2.24%
Cost Of Revenue $7.484M $3.124M
YoY Change 139.56% 30.93%
Gross Profit $10.36M $6.333M
YoY Change 63.57% -7.74%
Gross Profit Margin 58.06% 66.97%
Selling, General & Admin $19.38M $14.46M
YoY Change 34.08% 7.54%
% of Gross Profit 187.1% 228.26%
Research & Development $33.83M $17.27M
YoY Change 95.88% -6.69%
% of Gross Profit 326.61% 272.75%
Depreciation & Amortization $600.0K $600.0K
YoY Change 0.0% 20.0%
% of Gross Profit 5.79% 9.47%
Operating Expenses $53.22M $31.73M
YoY Change 67.72% -0.7%
Operating Profit -$42.86M -$25.40M
YoY Change 68.75% 0.42%
Interest Expense $26.16M $2.399M
YoY Change 990.45% 8.7%
% of Operating Profit
Other Income/Expense, Net $18.47M -$3.067M
YoY Change -702.09% 40.05%
Pretax Income -$50.46M -$28.46M
YoY Change 77.29% 3.57%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.535M -$13.31M
YoY Change -73.45% 1.65%
Net Earnings / Revenue -19.81% -140.78%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$0.04 -$194.2K
COMMON SHARES
Basic Shares Outstanding 80.96M
Diluted Shares Outstanding 80.96M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $275.0M $183.3M
YoY Change 50.02% 18.72%
Cash & Equivalents $275.0M $183.3M
Short-Term Investments
Other Short-Term Assets $4.003M $3.200M
YoY Change 25.09% -5.88%
Inventory $14.32M $1.209M
Prepaid Expenses
Receivables $26.19M $11.17M
Other Receivables $842.0K $900.0K
Total Short-Term Assets $320.3M $199.8M
YoY Change 60.33% 22.2%
LONG-TERM ASSETS
Property, Plant & Equipment $13.13M $12.36M
YoY Change 6.2% -63.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $48.48M $11.10M
YoY Change 336.79% -0.89%
Other Assets $1.126M $1.350M
YoY Change -16.59% -92.2%
Total Long-Term Assets $97.81M $68.77M
YoY Change 42.22% 7.8%
TOTAL ASSETS
Total Short-Term Assets $320.3M $199.8M
Total Long-Term Assets $97.81M $68.77M
Total Assets $418.2M $268.6M
YoY Change 55.7% 18.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.27M $21.30M
YoY Change -33.0% 23.84%
Accrued Expenses $59.91M $21.14M
YoY Change 183.4% 115.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.861M $21.80M
YoY Change -82.29% 131.91%
Total Short-Term Liabilities $70.60M $56.97M
YoY Change 23.93% 56.51%
LONG-TERM LIABILITIES
Long-Term Debt $71.21M $69.50M
YoY Change 2.45% -6.46%
Other Long-Term Liabilities $1.856M $7.338M
YoY Change -74.71% -72.52%
Total Long-Term Liabilities $1.856M $7.338M
YoY Change -74.71% -92.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.60M $56.97M
Total Long-Term Liabilities $1.856M $7.338M
Total Liabilities $169.9M $151.7M
YoY Change 11.96% -22.36%
SHAREHOLDERS EQUITY
Retained Earnings -$495.1M -$461.9M
YoY Change 7.19%
Common Stock $97.00K $86.00K
YoY Change 12.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.3M $60.48M
YoY Change
Total Liabilities & Shareholders Equity $418.2M $268.6M
YoY Change 55.7% 18.16%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$3.535M -$13.31M
YoY Change -73.45% 1.65%
Depreciation, Depletion And Amortization $600.0K $600.0K
YoY Change 0.0% 20.0%
Cash From Operating Activities -$34.46M -$17.41M
YoY Change 97.92% -38.52%
INVESTING ACTIVITIES
Capital Expenditures -$2.690M $690.0K
YoY Change -489.86% -204.55%
Acquisitions
YoY Change
Other Investing Activities -$2.148M -$1.750M
YoY Change 22.74% -4475.0%
Cash From Investing Activities -$4.838M -$1.060M
YoY Change 356.42% 73.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.40M 65.81M
YoY Change -62.93% 6.32%
NET CHANGE
Cash From Operating Activities -34.46M -17.41M
Cash From Investing Activities -4.838M -1.060M
Cash From Financing Activities 24.40M 65.81M
Net Change In Cash -14.90M 47.34M
YoY Change -131.47% 43.59%
FREE CASH FLOW
Cash From Operating Activities -$34.46M -$17.41M
Capital Expenditures -$2.690M $690.0K
Free Cash Flow -$31.77M -$18.10M
YoY Change 75.51% -34.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
August 31, 2025
dei Entity Central Index Key
EntityCentralIndexKey
0001429260
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Fortress Biotech, Inc.
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3427138
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3427138
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97495244
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2035000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1849000
CY2021Q2 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Current
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesCurrent
639000
CY2020Q4 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Current
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesCurrent
778000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
94877492
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35366
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5157386
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort Street, 9th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652-4500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
274992000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
233351000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26193000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23928000
CY2021Q2 us-gaap Inventory Net
InventoryNet
14315000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1404000
CY2021Q2 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
842000
CY2020Q4 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
744000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4003000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6723000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
320345000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
266150000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13126000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11923000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19731000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20487000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1645000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1645000
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
48484000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
17566000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13701000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14629000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1126000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1013000
CY2021Q2 us-gaap Assets
Assets
418158000
CY2020Q4 us-gaap Assets
Assets
333413000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
59906000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
45389000
CY2021Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4800000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
94877492
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
97000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
95000
CY2021Q2 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
78671
CY2021Q2 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
3861000
CY2020Q4 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
4522000
CY2020Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
0
CY2021Q2 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
263000
CY2020Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
0
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
603035000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
583000000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495117000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-482760000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
70602000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51760000
CY2021Q2 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Noncurrent
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesNoncurrent
7737000
CY2020Q4 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Noncurrent
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesNoncurrent
8323000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
52263000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
51677000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21906000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22891000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
565000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
863000
CY2021Q2 fbio Partner Company Installment Payments Licenses Noncurrent
PartnerCompanyInstallmentPaymentsLicensesNoncurrent
6435000
CY2020Q4 fbio Partner Company Installment Payments Licenses Noncurrent
PartnerCompanyInstallmentPaymentsLicensesNoncurrent
8137000
CY2021Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
12508000
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0
CY2021Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4287000
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1856000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1949000
CY2021Q2 us-gaap Liabilities
Liabilities
169857000
CY2020Q4 us-gaap Liabilities
Liabilities
136414000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2021Q2 fbio Preferred Stock Shares Designated
PreferredStockSharesDesignated
5000000
CY2020Q4 fbio Preferred Stock Shares Designated
PreferredStockSharesDesignated
5000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3427138
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3427138
CY2021Q2 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
25.00
CY2020Q4 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
25.00
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97495244
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
108281000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
100338000
CY2021Q2 us-gaap Minority Interest
MinorityInterest
140020000
CY2020Q4 us-gaap Minority Interest
MinorityInterest
96661000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
248301000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
196999000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
418158000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
333413000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15288000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9415000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
26007000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
21361000
CY2021Q2 fbio Collaboration Revenue
CollaborationRevenue
2400000
CY2020Q2 fbio Collaboration Revenue
CollaborationRevenue
0
fbio Collaboration Revenue
CollaborationRevenue
3200000
fbio Collaboration Revenue
CollaborationRevenue
0
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
155000
CY2020Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
42000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
223000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1014000
CY2021Q2 us-gaap Revenues
Revenues
17843000
CY2020Q2 us-gaap Revenues
Revenues
9457000
us-gaap Revenues
Revenues
29430000
us-gaap Revenues
Revenues
22375000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7484000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3124000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11392000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6934000
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
22831000
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15703000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
42859000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
30570000
CY2021Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
11003000
CY2020Q2 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1570000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
11129000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1820000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19382000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14456000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36924000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29975000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
60700000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
34853000
us-gaap Costs And Expenses
CostsAndExpenses
102304000
us-gaap Costs And Expenses
CostsAndExpenses
69299000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-42857000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25396000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72874000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46924000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
146000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
336000
us-gaap Investment Income Interest
InvestmentIncomeInterest
373000
us-gaap Investment Income Interest
InvestmentIncomeInterest
963000
CY2021Q2 fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
2760000
CY2020Q2 fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
3059000
fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
4949000
fbio Interest Expense And Finance Fees
InterestExpenseAndFinanceFees
6184000
CY2021Q2 fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
25005000
CY2020Q2 fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
0
fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
30918000
fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
0
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3925000
CY2020Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
344000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3925000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
386000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18466000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3067000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22417000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5607000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-24391000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-28463000
us-gaap Profit Loss
ProfitLoss
-50457000
us-gaap Profit Loss
ProfitLoss
-52531000
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-20856000
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-15149000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38100000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-26847000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3535000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-13314000
us-gaap Net Income Loss
NetIncomeLoss
-12357000
us-gaap Net Income Loss
NetIncomeLoss
-25684000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.30
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.42
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.62
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.80
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.26
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.22
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.47
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.41
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80962994
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68550494
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80907671
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66023367
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
244225000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
4350000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
137000
fbio Common Shares Issued For Subordinated Note Financial Interest Expenses
CommonSharesIssuedForSubordinatedNoteFinancialInterestExpenses
506000
fbio Common Shares Issuable For Interest Expenses
CommonSharesIssuableForInterestExpenses
313000
CY2021Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2008000
CY2021Q2 fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
25910000
CY2021Q2 us-gaap Dividends Common Stock
DividendsCommonStock
188000
CY2021Q2 fbio Adjustments To Additional Paid In Capital Stock Subsidiaries Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockSubsidiariesStockIssuedForResearchAndDevelopmentExpenses
3000
CY2021Q2 fbio Common Shares Issuable For Dividend On Partner Company Convertible Preferred Shares
CommonSharesIssuableForDividendOnPartnerCompanyConvertiblePreferredShares
263000
CY2021Q2 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
20856000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3535000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
248301000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
75285000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3748000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
90000
CY2020Q2 fbio Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
16203000
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1581000
CY2020Q2 fbio Stock Issued During Period Value Preferred Stock
StockIssuedDuringPeriodValuePreferredStock
-10436000
CY2020Q2 fbio Adjustments To Additional Paid In Capital Subsidiary Public Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering
34924000
CY2020Q2 fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
5537000
CY2020Q2 fbio Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses
21000
CY2020Q2 fbio Common Shares Issuable For Subordinated Note Financial Interest Expenses
CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses
500000
CY2020Q2 fbio Common Shares Issuable For Interest Expenses
CommonSharesIssuableForInterestExpenses
158000
CY2020Q2 us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
15149000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-13314000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
116858000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
196999000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
8123000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
137000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
4015000
fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
97332000
fbio Partner Companys Exercise Of Options For Cash
PartnerCompanysExerciseOfOptionsForCash
7000
fbio Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program
IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram
158000
us-gaap Dividends Common Stock
DividendsCommonStock
375000
fbio Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses
129000
fbio Common Shares Issuable For Dividend On Partner Company Convertible Preferred Shares
CommonSharesIssuableForDividendOnPartnerCompanyConvertiblePreferredShares
263000
us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
38100000
us-gaap Net Income Loss
NetIncomeLoss
-12357000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
248301000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
72532000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
7148000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
90000
fbio Issuance Of Common Stock For At Market Offering
IssuanceOfCommonStockForAtMarketOffering
22083000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
2788000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
72000
fbio Stock Issued During Period Value Preferred Stock
StockIssuedDuringPeriodValuePreferredStock
-23503000
fbio Adjustments To Additional Paid In Capital Subsidiary Public Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering
34924000
fbio Adjustments To Additional Paid In Capital Subsidiary At Market Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering
10447000
fbio Stock Issued During Period Value Cash Less Exercise Of Warrants
StockIssuedDuringPeriodValueCashLessExerciseOfWarrants
13000
fbio Adjustments To Additional Paid In Capital Subsidiary Employee Stock Purchase Plan
AdjustmentsToAdditionalPaidInCapitalSubsidiaryEmployeeStockPurchasePlan
169000
fbio Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses
21000
fbio Common Shares Issuable For Subordinated Note Financial Interest Expenses
CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses
500000
us-gaap Net Income Loss Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
26847000
us-gaap Net Income Loss
NetIncomeLoss
-25684000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
116858000
us-gaap Profit Loss
ProfitLoss
-50457000
us-gaap Profit Loss
ProfitLoss
-52531000
us-gaap Depreciation
Depreciation
1212000
us-gaap Depreciation
Depreciation
1103000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-57000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
76000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
903000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1407000
us-gaap Paid In Kind Interest
PaidInKindInterest
441000
us-gaap Paid In Kind Interest
PaidInKindInterest
305000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
1325000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
710000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
837000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
804000
us-gaap Share Based Compensation
ShareBasedCompensation
8123000
us-gaap Share Based Compensation
ShareBasedCompensation
7148000
fbio Issuance Of Common Stock For Research And Development Expenses
IssuanceOfCommonStockForResearchAndDevelopmentExpenses
129000
fbio Issuance Of Common Stock For Research And Development Expenses
IssuanceOfCommonStockForResearchAndDevelopmentExpenses
21000
fbio Common Shares Issuable For Dividend On Partner Company S Convertible Preferred Shares
CommonSharesIssuableForDividendOnPartnerCompanySConvertiblePreferredShares
263000
fbio Common Shares Issuable For Dividend On Partner Company S Convertible Preferred Shares
CommonSharesIssuableForDividendOnPartnerCompanySConvertiblePreferredShares
0
fbio Issuance Of Common Stock For Interest Expense
IssuanceOfCommonStockForInterestExpense
0
fbio Issuance Of Common Stock For Interest Expense
IssuanceOfCommonStockForInterestExpense
500000
fbio Common Stock Issued For Interest Expenses
CommonStockIssuedForInterestExpenses
0
fbio Common Stock Issued For Interest Expenses
CommonStockIssuedForInterestExpenses
506000
fbio Common Stock Issuable For Notes Interest Expense
CommonStockIssuableForNotesInterestExpense
0
fbio Common Stock Issuable For Notes Interest Expense
CommonStockIssuableForNotesInterestExpense
313000
fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
30918000
fbio Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
0
fbio Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
3925000
fbio Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
386000
fbio Research And Development Licenses Acquired Expense
ResearchAndDevelopmentLicensesAcquiredExpense
11000000
fbio Research And Development Licenses Acquired Expense
ResearchAndDevelopmentLicensesAcquiredExpense
1799000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2208000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2290000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12911000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
352000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
98000
us-gaap Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
71000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2795000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-930000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
113000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
192000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5834000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3882000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
51000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
0
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-40000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4800000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
fbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-880000
fbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-492000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-93000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-93000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56148000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46420000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
234996000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21104000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41641000
fbio Payment Of Costs Related To Partner Company S Preferred Stock Offering
PaymentOfCostsRelatedToPartnerCompanySPreferredStockOffering
13000
fbio Payment Of Costs Related To Partner Company S Preferred Stock Offering
PaymentOfCostsRelatedToPartnerCompanySPreferredStockOffering
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2800000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
fbio Proceeds From Partner Company Share Settled Notes
ProceedsFromPartnerCompanyShareSettledNotes
14332000
fbio Proceeds From Partner Company Share Settled Notes
ProceedsFromPartnerCompanyShareSettledNotes
0
fbio Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes
PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes
1532000
fbio Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes
PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
103087000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88563000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39304000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2750000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
1090000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2148000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1749000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
400000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5298000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2839000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
4015000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
2788000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
70000
fbio Payments For Costs Related To Purchase Of Treasury Stock
PaymentsForCostsRelatedToPurchaseOfTreasuryStock
0
fbio Payments For Costs Related To Purchase Of Treasury Stock
PaymentsForCostsRelatedToPurchaseOfTreasuryStock
2000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
25875000
fbio Payment Of Costs Related To Issuance Of Series Preferred Stock
PaymentOfCostsRelatedToIssuanceOfSeriesPreferredStock
0
fbio Payment Of Costs Related To Issuance Of Series Preferred Stock
PaymentOfCostsRelatedToIssuanceOfSeriesPreferredStock
2283000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23026000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
793000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
137000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
90000
fbio Proceeds From Subsidiary S Employee Stock Purchase Plan
ProceedsFromSubsidiarySEmployeeStockPurchasePlan
158000
fbio Proceeds From Subsidiary S Employee Stock Purchase Plan
ProceedsFromSubsidiarySEmployeeStockPurchasePlan
169000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
375000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
fbio Proceeds From Partner Companies Sale Of Stock
ProceedsFromPartnerCompaniesSaleOfStock
0
fbio Proceeds From Partner Companies Sale Of Stock
ProceedsFromPartnerCompaniesSaleOfStock
37230000
fbio Payment Of Costs Related To Partner Companies Sale Of Stock
PaymentOfCostsRelatedToPartnerCompaniesSaleOfStock
0
fbio Payment Of Costs Related To Partner Companies Sale Of Stock
PaymentOfCostsRelatedToPartnerCompaniesSaleOfStock
2303000
fbio Proceeds From Issuance Of Subsidiaries At Market Offering
ProceedsFromIssuanceOfSubsidiariesAtMarketOffering
99384000
fbio Proceeds From Issuance Of Subsidiaries At Market Offering
ProceedsFromIssuanceOfSubsidiariesAtMarketOffering
10689000
fbio Payment Of Cost Related To Subsidiaries At The Market Offering
PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering
2136000
fbio Payment Of Cost Related To Subsidiaries At The Market Offering
PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering
242000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
153432000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
276637000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199852000
us-gaap Interest Paid Net
InterestPaidNet
3339000
us-gaap Interest Paid Net
InterestPaidNet
3165000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
504000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
fbio Settlement Of Restricted Shares Units Into Common Stock
SettlementOfRestrictedSharesUnitsIntoCommonStock
2000
fbio Settlement Of Restricted Shares Units Into Common Stock
SettlementOfRestrictedSharesUnitsIntoCommonStock
2000
fbio Common Shares Issued For2017 Subordinated Note Financing Interest Expense
CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense
0
fbio Common Shares Issued For2017 Subordinated Note Financing Interest Expense
CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense
500000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
298000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
127000
fbio Unpaid Debt Offering Cost
UnpaidDebtOfferingCost
0
fbio Unpaid Debt Offering Cost
UnpaidDebtOfferingCost
61000
fbio Unpaid Partner Companys Debt Offering Cost
UnpaidPartnerCompanysDebtOfferingCost
200000
fbio Unpaid Partner Companys Debt Offering Cost
UnpaidPartnerCompanysDebtOfferingCost
0
fbio Unpaid Partner Companys Deferred Offering Cost
UnpaidPartnerCompanysDeferredOfferingCost
75000
fbio Unpaid Partner Companys Deferred Offering Cost
UnpaidPartnerCompanysDeferredOfferingCost
72000
fbio Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes
PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes
362000
fbio Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes
PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes
0
fbio Unpaid At Market Offering Cost
UnpaidAtMarketOfferingCost
0
fbio Unpaid At Market Offering Cost
UnpaidAtMarketOfferingCost
156000
fbio Unpaid Preferred Offering Cost
UnpaidPreferredOfferingCost
0
fbio Unpaid Preferred Offering Cost
UnpaidPreferredOfferingCost
92000
fbio Unpaid Research And Development License Acquired
UnpaidResearchAndDevelopmentLicenseAcquired
8250000
fbio Unpaid Research And Development License Acquired
UnpaidResearchAndDevelopmentLicenseAcquired
1300000
fbio Lease Liabilities Arising From Obtaining Right Of Use Assets
LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
81000
fbio Lease Liabilities Arising From Obtaining Right Of Use Assets
LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes, and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p>
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7978000
CY2021Q2 us-gaap Inventory Net
InventoryNet
14315000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
16600000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
274992000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
183278000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1645000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16574000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
276637000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199852000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="background-color:#ffffff;font-weight:bold;">Reclassifications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-weight:bold;visibility:hidden;">​</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain comparative figures have been reclassified to conform to the current year presentation. The Company reclassified certain return reserves related to accounts receivable balances of $4.6 million from accounts receivable to current liabilities on the condensed consolidated balance sheet at December 31, 2020. This reclassification was deemed to be immaterial.</p>
CY2020Q4 fbio Return Reserves Related To Accounts Receivable Reclassified To Current Liabilities
ReturnReservesRelatedToAccountsReceivableReclassifiedToCurrentLiabilities
4600000
CY2021Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
4907000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1404000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
5700000
CY2020Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
0
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
0
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9408000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1404000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18689000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6766000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13126000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11923000
CY2021Q2 us-gaap Depreciation
Depreciation
600000
CY2020Q2 us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
1200000
us-gaap Depreciation
Depreciation
1100000
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
48484000
CY2021Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
4287000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
17566000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2021Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.1100
CY2021Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
7737000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
8323000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
52263000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
51677000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
8700000
CY2021Q2 fbio Partner Company Installment Payments Licenses Current Gross
PartnerCompanyInstallmentPaymentsLicensesCurrentGross
4500000
CY2021Q2 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Current
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesCurrent
639000
CY2021Q2 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
3861000
CY2021Q2 fbio Partner Company Installment Payments Licenses Noncurrent Gross
PartnerCompanyInstallmentPaymentsLicensesNoncurrentGross
7000000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
565000
CY2021Q2 fbio Partner Company Installment Payments Licenses Noncurrent
PartnerCompanyInstallmentPaymentsLicensesNoncurrent
6435000
CY2021Q2 fbio Partner Company Installment Payments Licenses
PartnerCompanyInstallmentPaymentsLicenses
10296000
CY2020Q4 fbio Partner Company Installment Payments Licenses Current Gross
PartnerCompanyInstallmentPaymentsLicensesCurrentGross
5300000
CY2020Q4 fbio Imputed Interest Related To Partner Company Installment Payments Licenses Current
ImputedInterestRelatedToPartnerCompanyInstallmentPaymentsLicensesCurrent
778000
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19003000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
18606000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5302000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3977000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13701000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14629000
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2020Q4 fbio Partner Company Installment Payments Licenses Current
PartnerCompanyInstallmentPaymentsLicensesCurrent
4522000
CY2020Q4 fbio Partner Company Installment Payments Licenses Noncurrent Gross
PartnerCompanyInstallmentPaymentsLicensesNoncurrentGross
9000000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
863000
CY2020Q4 fbio Partner Company Installment Payments Licenses Noncurrent
PartnerCompanyInstallmentPaymentsLicensesNoncurrent
8137000
CY2020Q4 fbio Partner Company Installment Payments Licenses
PartnerCompanyInstallmentPaymentsLicenses
12659000
CY2021Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2166000
CY2021Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
594000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
2760000
CY2020Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2399000
CY2020Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
660000
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
3059000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4046000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
903000
us-gaap Interest Expense Debt
InterestExpenseDebt
4949000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4777000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1407000
us-gaap Interest Expense Debt
InterestExpenseDebt
6184000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
14271000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11412000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1205000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1236000
CY2021Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5207000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
6701000
CY2021Q2 fbio Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
4063000
CY2020Q4 fbio Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
5007000
CY2021Q2 fbio Accrued Research And Development Expense Manufacturing
AccruedResearchAndDevelopmentExpenseManufacturing
0
CY2020Q4 fbio Accrued Research And Development Expense Manufacturing
AccruedResearchAndDevelopmentExpenseManufacturing
518000
CY2021Q2 fbio Research And Development Expense License Maintenance Fees
ResearchAndDevelopmentExpenseLicenseMaintenanceFees
8000000
CY2020Q4 fbio Research And Development Expense License Maintenance Fees
ResearchAndDevelopmentExpenseLicenseMaintenanceFees
0
CY2021Q2 fbio Accrued Research And Development Expense License Maintenance Fees
AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees
627000
CY2020Q4 fbio Accrued Research And Development Expense License Maintenance Fees
AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees
461000
CY2021Q2 fbio Accrued Research And Development Expense Milestones
AccruedResearchAndDevelopmentExpenseMilestones
1115000
CY2020Q4 fbio Accrued Research And Development Expense Milestones
AccruedResearchAndDevelopmentExpenseMilestones
600000
CY2021Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3340000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2682000
CY2021Q2 fbio Accrued Coupon Expense Current
AccruedCouponExpenseCurrent
18609000
CY2020Q4 fbio Accrued Coupon Expense Current
AccruedCouponExpenseCurrent
12869000
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
136000
CY2021Q2 fbio Accrued Return Reserve Current
AccruedReturnReserveCurrent
2099000
CY2020Q4 fbio Accrued Return Reserve Current
AccruedReturnReserveCurrent
2580000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1370000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1187000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59906000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45389000
CY2021Q2 fbio Minority Interest Equity Share
MinorityInterestEquityShare
178120000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-38100000
CY2021Q2 us-gaap Minority Interest
MinorityInterest
140020000
CY2020Q4 fbio Minority Interest Equity Share
MinorityInterestEquityShare
153120000
CY2020 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-56459000
CY2020Q4 us-gaap Minority Interest
MinorityInterest
96661000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21955984
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18759552
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4350000
CY2021Q2 fbio Tangible Assets Net
TangibleAssetsNet
404457000
CY2021Q2 us-gaap Assets
Assets
418158000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3748000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8123000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7148000
fbio Class Of Warrant Or Right Forfeited Weighted Average Intrinsic Value
ClassOfWarrantOrRightForfeitedWeightedAverageIntrinsicValue
0
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4505621
CY2021Q2 fbio Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
3.20
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1053490
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.02
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
647482
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P2Y7M17D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.88
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1028490
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.02
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
824878
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P2Y1M24D
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4590621
CY2020Q4 fbio Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
3.17
CY2020Q4 fbio Class Of Warrant Or Right Weighted Average Intrinsic Value
ClassOfWarrantOrRightWeightedAverageIntrinsicValue
607848
CY2020 fbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P4Y10M6D
fbio Class Of Warrant Or Right Number Of Shares Expired
ClassOfWarrantOrRightNumberOfSharesExpired
60000
fbio Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
1.37
fbio Class Of Warrant Or Right Expired Weighted Average Intrinsic Value
ClassOfWarrantOrRightExpiredWeightedAverageIntrinsicValue
0
fbio Class Of Warrant Or Right Number Of Shares Forfeited
ClassOfWarrantOrRightNumberOfSharesForfeited
25000
fbio Class Of Warrant Or Right Forfeited Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedWeightedAverageExercisePrice
3.00
CY2021Q2 fbio Class Of Warrant Or Right Weighted Average Intrinsic Value
ClassOfWarrantOrRightWeightedAverageIntrinsicValue
1958891
fbio Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P4Y5M8D
fbio Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
4370621
fbio Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
3.23
fbio Class Of Warrant Or Right Exercisable Weighted Average Intrinsic Value
ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue
1754141
fbio Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife
P4Y4M9D
fbio Annual Management Services Agreement Fee Income
AnnualManagementServicesAgreementFeeIncome
4500
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2021Q2 us-gaap Revenues
Revenues
17843000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7484000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6535000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33834000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12847000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18466000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-24391000
CY2020Q2 us-gaap Revenues
Revenues
9457000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3124000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3400000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17273000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11056000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3067000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-28463000
us-gaap Revenues
Revenues
29430000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11392000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11605000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53988000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25319000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22417000
us-gaap Profit Loss
ProfitLoss
-50457000
us-gaap Revenues
Revenues
22375000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6934000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8079000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32390000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21896000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5607000
us-gaap Profit Loss
ProfitLoss
-52531000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13701000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14629000
CY2020Q4 fbio Tangible Assets Net
TangibleAssetsNet
318784000
CY2020Q4 us-gaap Assets
Assets
333413000
fbio Number Of Marketed Products
NumberOfMarketedProducts
7
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15288000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9415000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
26007000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
21361000
CY2021Q2 fbio Collaboration Revenue
CollaborationRevenue
2400000
CY2020Q2 fbio Collaboration Revenue
CollaborationRevenue
0
fbio Collaboration Revenue
CollaborationRevenue
3200000
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
155000
CY2020Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
42000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
223000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1014000
CY2021Q2 us-gaap Revenues
Revenues
17843000
CY2020Q2 us-gaap Revenues
Revenues
9457000
us-gaap Revenues
Revenues
29430000
us-gaap Revenues
Revenues
22375000
fbio Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return
MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn
0.80
fbio Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return
MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn
0.80

Files In Submission

Name View Source Status
0001558370-21-011812-index-headers.html Edgar Link pending
0001558370-21-011812-index.html Edgar Link pending
0001558370-21-011812.txt Edgar Link pending
0001558370-21-011812-xbrl.zip Edgar Link pending
fbio-20210630.xsd Edgar Link pending
fbio-20210630x10q.htm Edgar Link pending
fbio-20210630x10q_htm.xml Edgar Link completed
fbio-20210630xex10d1.htm Edgar Link pending
fbio-20210630xex10d2.htm Edgar Link pending
fbio-20210630xex10d3.htm Edgar Link pending
fbio-20210630xex31d1.htm Edgar Link pending
fbio-20210630xex31d2.htm Edgar Link pending
fbio-20210630xex32d1.htm Edgar Link pending
fbio-20210630xex32d2.htm Edgar Link pending
fbio-20210630_cal.xml Edgar Link unprocessable
fbio-20210630_def.xml Edgar Link unprocessable
fbio-20210630_lab.xml Edgar Link unprocessable
fbio-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending